Relmada Therapeutics Stock Working Capital
| RLMD Stock | USD 3.02 0.12 4.14% |
Relmada Therapeutics fundamentals help investors to digest information that contributes to Relmada Therapeutics' financial success or failures. It also enables traders to predict the movement of Relmada Stock. The fundamental analysis module provides a way to measure Relmada Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Relmada Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Net Working Capital | 85.3 M | 85.6 M | |
| Change In Working Capital | 3.1 M | 3.2 M |
Relmada | Working Capital |
Relmada Therapeutics Company Working Capital Analysis
Relmada Therapeutics' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Relmada Therapeutics Working Capital | 85.31 M |
Most of Relmada Therapeutics' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Relmada Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Relmada Working Capital Driver Correlations
Understanding the fundamental principles of building solid financial models for Relmada Therapeutics is extremely important. It helps to project a fair market value of Relmada Stock properly, considering its historical fundamentals such as Working Capital. Since Relmada Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Relmada Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Relmada Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
Relmada Capital Surpluse
Capital Surpluse |
|
Based on the company's disclosures, Relmada Therapeutics has a Working Capital of 85.31 M. This is 79.96% lower than that of the Pharmaceuticals sector and 84.16% lower than that of the Health Care industry. The working capital for all United States stocks is 94.23% higher than that of the company.
Relmada Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Relmada Therapeutics' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Relmada Therapeutics could also be used in its relative valuation, which is a method of valuing Relmada Therapeutics by comparing valuation metrics of similar companies.Relmada Therapeutics is currently under evaluation in working capital category among its peers.
Relmada Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Relmada Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Relmada Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Relmada Fundamentals
| Return On Equity | -1.0 | ||||
| Return On Asset | -0.59 | ||||
| Current Valuation | 37.01 M | ||||
| Shares Outstanding | 30.17 M | ||||
| Shares Owned By Insiders | 8.04 % | ||||
| Shares Owned By Institutions | 46.06 % | ||||
| Number Of Shares Shorted | 1.15 M | ||||
| Price To Earning | (1.27) X | ||||
| Price To Book | 1.91 X | ||||
| EBITDA | 4.91 M | ||||
| Net Income | (98.79 M) | ||||
| Cash And Equivalents | 211.96 M | ||||
| Cash Per Share | 7.05 X | ||||
| Total Debt | 12.19 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 11.40 X | ||||
| Book Value Per Share | 2.84 X | ||||
| Cash Flow From Operations | (51.66 M) | ||||
| Short Ratio | 4.52 X | ||||
| Earnings Per Share | (2.86) X | ||||
| Target Price | 12.0 | ||||
| Number Of Employees | 20 | ||||
| Beta | 0.42 | ||||
| Market Capitalization | 91.13 M | ||||
| Total Asset | 97.55 M | ||||
| Retained Earnings | (560.9 M) | ||||
| Working Capital | 85.31 M | ||||
| Current Asset | 9.3 M | ||||
| Current Liabilities | 3.06 M | ||||
| Net Asset | 97.55 M |
About Relmada Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Relmada Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Relmada Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Relmada Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Relmada Therapeutics is a strong investment it is important to analyze Relmada Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Relmada Therapeutics' future performance. For an informed investment choice regarding Relmada Stock, refer to the following important reports:Check out Relmada Therapeutics Piotroski F Score and Relmada Therapeutics Altman Z Score analysis. For information on how to trade Relmada Stock refer to our How to Trade Relmada Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Relmada Therapeutics. If investors know Relmada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Relmada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.86) | Return On Assets (0.59) | Return On Equity (1.00) |
The market value of Relmada Therapeutics is measured differently than its book value, which is the value of Relmada that is recorded on the company's balance sheet. Investors also form their own opinion of Relmada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Relmada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Relmada Therapeutics' market value can be influenced by many factors that don't directly affect Relmada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Relmada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Relmada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Relmada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.